JPWO2022152285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022152285A5 JPWO2022152285A5 JP2023542963A JP2023542963A JPWO2022152285A5 JP WO2022152285 A5 JPWO2022152285 A5 JP WO2022152285A5 JP 2023542963 A JP2023542963 A JP 2023542963A JP 2023542963 A JP2023542963 A JP 2023542963A JP WO2022152285 A5 JPWO2022152285 A5 JP WO2022152285A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940127121 immunoconjugate Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 101001004924 Homo sapiens Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 1
- 102000052917 human LRRC32 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110065290 | 2021-01-18 | ||
| CN202110065290.8 | 2021-01-18 | ||
| PCT/CN2022/072265 WO2022152285A1 (zh) | 2021-01-18 | 2022-01-17 | Garp蛋白抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502670A JP2024502670A (ja) | 2024-01-22 |
| JPWO2022152285A5 true JPWO2022152285A5 (https=) | 2025-01-27 |
| JP2024502670A5 JP2024502670A5 (https=) | 2025-01-27 |
Family
ID=82446943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542963A Pending JP2024502670A (ja) | 2021-01-18 | 2022-01-17 | Ｇａｒｐタンパク質抗体及びその適用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240117034A1 (https=) |
| EP (1) | EP4279509A4 (https=) |
| JP (1) | JP2024502670A (https=) |
| KR (1) | KR20230169936A (https=) |
| CN (1) | CN116710125A (https=) |
| AU (1) | AU2022207029A1 (https=) |
| BR (1) | BR112023014319A2 (https=) |
| CA (1) | CA3208624A1 (https=) |
| IL (1) | IL304453A (https=) |
| TW (1) | TW202241955A (https=) |
| WO (1) | WO2022152285A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240042020A1 (en) * | 2022-07-29 | 2024-02-08 | Abbvie Biotherapeutics Inc. | Anti-garp-tgf-beta1/pd-1 combination therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO2015015003A1 (en) * | 2013-08-01 | 2015-02-05 | Université Catholique de Louvain | Anti-garp protein and uses thereof |
| WO2016125017A1 (en) * | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| TWI909341B (zh) * | 2015-09-24 | 2025-12-21 | 日商第一三共股份有限公司 | 抗garp抗體及其製造方法及用途 |
| WO2017156500A1 (en) * | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgfb1-binding immunoglobulins and use thereof |
| US20190292254A1 (en) * | 2016-07-14 | 2019-09-26 | Scholar Rock, Inc. | TGFBeta Antibodies, Methods and Uses |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| WO2021231732A1 (en) * | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
-
2022
- 2022-01-17 CA CA3208624A patent/CA3208624A1/en active Pending
- 2022-01-17 CN CN202280010421.5A patent/CN116710125A/zh active Pending
- 2022-01-17 EP EP22739160.4A patent/EP4279509A4/en active Pending
- 2022-01-17 BR BR112023014319A patent/BR112023014319A2/pt unknown
- 2022-01-17 TW TW111101854A patent/TW202241955A/zh unknown
- 2022-01-17 US US18/272,826 patent/US20240117034A1/en active Pending
- 2022-01-17 JP JP2023542963A patent/JP2024502670A/ja active Pending
- 2022-01-17 KR KR1020237027472A patent/KR20230169936A/ko active Pending
- 2022-01-17 AU AU2022207029A patent/AU2022207029A1/en active Pending
- 2022-01-17 WO PCT/CN2022/072265 patent/WO2022152285A1/zh not_active Ceased
-
2023
- 2023-07-13 IL IL304453A patent/IL304453A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516973A5 (https=) | ||
| JP2023002562A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021515568A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2021516975A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020522280A5 (https=) | ||
| JPWO2019175223A5 (https=) | ||
| JPWO2019175226A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2024024114A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| JP2024546939A (ja) | ヒトｃｄ７３と結合する抗体、その製造方法と使用 | |
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JPWO2020227457A5 (https=) | ||
| JPWO2020257289A5 (https=) | ||
| JPWO2022152285A5 (https=) |